Insiders Trades
ALK-Abelló Stock: price and insider trades · Denmark
No insider purchase over the last 90 days. The latest was filed 21 Feb 2025.
ALK-Abelló: what insiders have been doing
Every trade that managers of ALK-Abelló disclose to Finanstilsynet DK is tracked on this page. The company sits in the Health Care sector and is based in Hørsholm, Denmark. It was founded in 1923. Its latest reported headcount is 2,812 employees (2024). In the past year (18 October 2025 to 18 October 2026), 1 filing came from 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought ALK-Abelló shares on the open market in the past twelve months.
With 1 filing in twelve months, the company is quieter than the median of 4 filings across the 74 companies we follow on the same exchange. Since 2007, the database holds 24 purchases and 12 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from Finanstilsynet DK. Past trades are no guide to future returns.
Insider Decl.
89
Thresholds
n/a
Buy Volume
€26B
24 ops. · all time
Sell Volume
€8B
12 ops. · all time
Who traded when
BuySaleUnknown1 buy
Analyst consensus: bullish or bearish?
Analysts rate ALK-Abelló Strong Buy (bullish), based on 4 analysts. Average price target: DKK 293.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,088 of 24,148 companies
64.0
score / 100
Value42
Quality86
FCF yld3.3%
Earn yld2.7%
EV/EBITDA22.4x
ROE21%
Gross mgn67%
Net mgn19%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
DKK 199.70
Analyst consensus
4 analystsStrong buy
DKK 285.00Target DKK 293.75(+47%)DKK 300.00
Income statement
RevenueDKK 6.3B
Gross profitDKK 4.2B67% margin
EBITDADKK 2B32% margin
Net incomeDKK 1.2B19.9% margin
Valuation
PER (trailing)32.8x
PER (forward)27.6x
P/Book6.4x
Beta0.70
Balance sheet & cash
Market capDKK 44.3B
Total debtDKK 418M
Free Cash FlowDKK 1.5B
Debt / Equity6%
Profitability & ownership
ROE21.2%
ROA12.7%
% insiders0.0%
% institutions63.9%
Last declaration on 1 June 2026
Declarations89 total
00ShareOutside a market placeISIN DK0061802139DK:1445832
152.66 shares0ShareOutside a market placeISIN DK0061802139DK:1346969
1,606 shares@ DKK 155.680.0005% mcap0.0% of flowShareNASDAQ CopenhagenISIN DK0061802139DK:1344674
Canonical exit: 21 May 2025 (T+90)
35,535 shares@ DKK 75.720.0055% mcap0.0% of flowShareOutside a market placeISIN DK0061802139DK:1313156
Canonical exit: 24 Nov 2024 (T+90)
1,880 shares@ DKK 132.600.0005% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0061802139DK:1279324
Canonical exit: 2 Jun 2024 (T+90)
130 shares0ShareOutside a market placeISIN DK0061802139DK:1279059
8,400 shares@ DKK 130.9240.0023% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0061802139DK:1274257
Canonical exit: 12 May 2024 (T+90)
70,000 shares@ DKK 59.160.0085% mcap0.0% of flowShareOutside a market placeISIN DK0061802139DK:1274175
Canonical exit: 9 May 2024 (T+90)
103 shares0ShareOutside a market placeISIN DK0061802139DK:1210885
1,834 shares@ DKK 108.200.0004% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0061802139DK:1205683
Canonical exit: 9 May 2023 (T+90)
50,000 shares@ DKK 144.700.015% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0061802139DK:1177638
201,760 shares@ DKK 57.720.024% mcap0.0% of flowShareOutside a market placeISIN DK0061802139DK:1175790
Canonical exit: 10 Nov 2022 (T+90)
84,000 shares@ DKK 128.660.022% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0061802139DK:1162652
86,692 shares@ DKK 41.120.0074% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0061802139DK:1162045
Canonical exit: 14 Aug 2022 (T+90)
2,515 shares0ShareNASDAQ CopenhagenISIN DK0060027142DK:1143949
6,514 shares@ DKK 3,090.520.042% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1127037
1,050.83 shares@ DKK 866.290.0019% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1126582
Canonical exit: 20 Feb 2022 (T+90)
7,736 shares@ DKK 802.280.013% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1125266
Canonical exit: 10 Feb 2022 (T+90)
201 shares@ DKK 2,962.000.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1110103
Canonical exit: 11 Nov 2021 (T+90)
450 shares@ DKK 2,726.000.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1030972
Canonical exit: 4 Aug 2021 (T+90)
2,619 shares@ DKK 2,425.000.013% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1009110
5,000 shares@ DKK 2,600.000.027% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1008042
3,200 shares@ DKK 2,621.000.017% mcap0.0% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1007813
2,639 shares0ShareNasdaq CopenhagenISIN DK0060027142DK:1007812
17,068 shares5.9% of flowShareNasdaq CopenhagenISIN DK0060027142DK:1006475
25 of 89 declarations
About ALK-Abelló
ALK-Abelló is a company focused on developing treatments for allergies, particularly immunotherapies. It is listed on the XCSE exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
